H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on OpGen Inc (OPGN) today and set a price target of $6. The company’s shares opened today at $1.33, close to its 52-week low of $1.18.
According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -13.9% and a 22.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Bausch Health Companies Inc, and Aerpio Pharmaceuticals Inc.
Currently, the analyst consensus on OpGen Inc is a Moderate Buy with an average price target of $6.
See today’s analyst top recommended stocks >>
Based on OpGen Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $3.33 million. In comparison, last year the company had a GAAP net loss of $3.27 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OpGen, Inc. operates as a precision medicine company using molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for global healthcare settings, helping to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. The company was founded on January 22, 2001 and is headquartered in Gaithersburg, MD.
